Description:
- Deliver drugs for cancer and other diseases
Abstract
Using a newly discovered NAD+ analogue with excellent activity for poly-ADP-ribosylation, functionalized poly-ADP-ribose polymers were robustly synthesized. The functionalized poly-ADP-ribose polymers provide a novel type of drug carrier that allows for facile conjugation of monoclonal antibodies and therapeutic payloads in high ratios. The resulting polymer-based conjugates with antibody and cytotoxic drugs show great potency and specificity for killing cancer cells. These functionalized poly-ADP-ribose polymers provide a general and versatile platform for the development of new classes of polymer-based drug conjugates for therapeutic delivery.
Benefit
- Carrier allows for the facile conjugation of monoclonal antibodies and payloads in high ratios
- Great potency and specificity for killing cancer cells
- Potential to deliver drugs to target cells in a variety of diseases for treatments or research use
- General and versatile platform for therapeutic delivery
Market Application
Formulating drugs and identifying vehicles for drug delivery is a key aspect of preclinical drug development. Various drug carriers have been developed, but many lack crucial desirable properties, such as high functionalization, ease of manufacture, robust structure, and compatibility with different drug classes. New concepts for delivery platforms are needed.
Publications
Nat Commun. 2019, 13;10(1):4196
Other
Stage of Development
- Successful proof-of-concept testing in HER2-positive and –negative breast cancer cells
- Demonstrated stability, efficacy, and specificity
Intellectual Property Status
US patent issued 11,497,787